-continued

```
<220> FEATURE:
<223> OTHER INFORMATION: HER3 binding site for 10D1-derived clones

<400> SEQUENCE: 229

Cys Phe Gly Pro Asn Pro Asn Gln Cys Cys His Asp Glu Cys Ala Gly
1               5                   10                  15

Gly Cys


<210> SEQ ID NO 230
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: 10D1 binding site motif 1

<400> SEQUENCE: 230

Pro Asn Pro Asn Gln
1               5


<210> SEQ ID NO 231
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: 10D1 binding site motif 2

<400> SEQUENCE: 231

Asp Glu Cys Ala Gly
1               5
```

1-23. (canceled)

24. An antigen-binding molecule comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the antigen-binding molecule specifically binds to HER3, and wherein binding to HER3 comprises contact with one or more amino acid residues of the region of HER3 shown in SEQ ID NO:229.

25. The antigen-binding molecule according to claim **24**, wherein the antigen-binding molecule comprises:

a VH region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:43

HC-CDR2 having the amino acid sequence of SEQ ID NO:46

HC-CDR3 having the amino acid sequence of SEQ ID NO:51; and

a VL region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:91

LC-CDR2 having the amino acid sequence of SEQ ID NO:94

LC-CDR3 having the amino acid sequence of SEQ ID NO:99.

26. The antigen-binding molecule according to claim **24**, wherein the antigen-binding molecule comprises:

(a)

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:44

HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or

(b)

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:44

HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:89

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or

(c)

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:44

HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and